DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "Hypereosinophilic Syndrome - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders).

Companies Mentioned

Bristol-Myers Squibb Co GlaxoSmithKline Plc Knopp Biosciences LLC Kyowa Hakko Kirin Co Ltd Stemline Therapeutics Inc

Key Topics Covered

Introduction Report Coverage Hypereosinophilic Syndrome - Overview Hypereosinophilic Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Hypereosinophilic Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development Bristol-Myers Squibb Co GlaxoSmithKline Plc Knopp Biosciences LLC Kyowa Hakko Kirin Co Ltd Stemline Therapeutics Inc Hypereosinophilic Syndrome - Drug Profiles benralizumab - Drug Profile Product Description Mechanism Of Action R&D Progress dasatinib - Drug Profile Product Description Mechanism Of Action R&D Progress dexpramipexole dihydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress mepolizumab - Drug Profile Product Description Mechanism Of Action R&D Progress SL-401 - Drug Profile Product Description Mechanism Of Action R&D Progress Hypereosinophilic Syndrome - Dormant Projects Hypereosinophilic Syndrome - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/xksj4w/pipeline_review?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006528/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 02:15 PM/DISC: 06/05/2018 02:15 PM

http://www.businesswire.com/news/home/20180605006528/en